X0306 4 2016-02-03 true 0001432732 TriVascular Technologies, Inc. TRIV 0001605343 O'Quinn Shari L C/O TRIVASCULAR TECHNOLOGIES, INC. 3910 BRICKWAY BLVD. SANTA ROSA CA 95403 false true false false VP Clinical/Regulatory Affairs Common Stock 2016-02-03 4 M false 9400.00 A 9400.00 D Common Stock 2016-02-03 4 F false 3549.00 5.62 D 5851.00 D Common Stock 2016-02-03 4 D false 5851.00 D 0.00 D Common Stock 2016-02-03 4 M false 41838.00 2.43 A 41838.00 D Common Stock 2016-02-03 4 F false 18092.00 5.62 D 23746.00 D Common Stock 2016-02-03 4 D false 23746.00 D 0.00 D Restricted Stock Units (RSU) 2016-02-03 4 M false 9400.00 0.00 D Common Stock 9400.00 0.00 D Stock Options (Right to buy) 2.43 2016-02-03 4 M false 41838.00 0.00 D 2022-08-29 Common Stock 41838.00 0.00 D Each RSU represents a contingent right to receive one share of TRIV common stock. These shares were withheld by the issuer to satisfy tax withholding obligations and calculated for the purposes of the deemed settlement of the RSUs, contingent upon the closing of the Merger (as defined below), utilizing the closing price of the issuers common stock on January 28, 2016. These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the Merger). In connection with the closing of the Merger, the reporting person received 0.6312 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016. These shares were withheld by the issuer as payment of the exercise price and to satisfy tax withholding obligations, and calculated for the purposes of the deemed exercise of the options, contingent upon the closing of the Merger, utilizing the closing price of the issuers common stock on January 28, 2016. These restricted stock units became 100% vested in connection with the Merger. These stock options became 100% vested in connection with the Merger. /s/ Michael Kramer, Attorney-In-Fact Shari L. O'Quinn 2016-02-04